Last reviewed · How we verify
Gliclazide MR-based glucose lowering
Gliclazide is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Gliclazide is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Gliclazide MR-based glucose lowering |
|---|---|
| Sponsor | The George Institute |
| Drug class | Sulfonylurea |
| Target | ATP-sensitive potassium channel (KATP channel) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Gliclazide binds to and closes ATP-sensitive potassium channels on the surface of pancreatic beta cells, leading to cell depolarization and opening of voltage-gated calcium channels. This influx of calcium triggers the release of stored insulin into the bloodstream, thereby lowering blood glucose levels. The modified-release (MR) formulation provides sustained drug delivery over 24 hours, allowing once-daily dosing.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Gastrointestinal disturbances
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gliclazide MR-based glucose lowering CI brief — competitive landscape report
- Gliclazide MR-based glucose lowering updates RSS · CI watch RSS
- The George Institute portfolio CI